The World Health Organization Director-General Tedros Adhanom Ghebreyesus said Monday that a clinical trial of malaria drug hydroxychloroquine on COVID-19 patients came to "a temporary pause," while the safety data is reviewed by the Data Safety Monitoring Board.
"The Executive Group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity Trial while the safety data is reviewed by the Data Safety Monitoring Board," Tedros told a press briefing.
